THE FIRST-AND-ONLY BISPECIFIC ANTIBODY APPROVED FOR BOTH 3L+ DLBCL AND 3L+ FL1
Choose an indication:
Granted accelerated approvals based on overall response
rate and durability of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials.